DB
ABEO icon

Dmitry Balyasny’s Abeona Therapeutics ABEO Stock Holding History

Dmitry Balyasny’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-589,847
Closed -$2.64M – 2953
2026
Q1 		$2.64M Sell
589,847
-1,890
-0.3% -$9.45K ﹤0.01% 1664
2025
Q4 		$3.12M Buy
+591,737
New +$2.98M ﹤0.01% 1647
2025
Q2 		– Sell
-73,849
Closed -$352K – 2740
2025
Q1 		$352K Buy
73,849
+39,721
+116% +$216K ﹤0.01% 2393
2024
Q4 		$190K Buy
+34,128
New +$210K ﹤0.01% 2535
2024
Q2 		– Sell
-19,026
Closed -$138K – 2504
2024
Q1 		$138K Buy
+19,026
New +$121K ﹤0.01% 2469
2018
Q4 		– Sell
-1,609
Closed -$515K – 1347
2018
Q3 		$515K Buy
1,609
+709
+79% +$252K ﹤0.01% 1371
2018
Q2 		$360K Buy
+900
New +$393K ﹤0.01% 1452
2018
Q1 		– Sell
-8,000
Closed -$3.17M – 1889
2017
Q4 		$3.17M Buy
+8,000
New +$3.31M 0.01% 1003

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dmitry Balyasny's ABEO Position: Q2 2026 in Review

Dmitry Balyasny sold out of Abeona Therapeutics (ABEO) in Q2 2026, closing a stake of 589,847 shares — an estimated $2.64M sold.

Dmitry Balyasny first reported a position in ABEO in Q4 2017 and held it in 8 quarters. The position peaked at $3.17M in Q4 2017. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Dmitry Balyasny reported no remaining Abeona Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 589,847 Abeona Therapeutics shares in Q2 2026, an estimated $2.64M.
  • Dmitry Balyasny first reported a position in Abeona Therapeutics in Q4 2017 and held it in 8 quarters.
  • Dmitry Balyasny's Abeona Therapeutics position peaked at $3.17M in Q4 2017.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.